A Study to Test Combination Treatments in Participants With Advanced Gastric Cancer

Part of paid clinical trials in Phoenix, Arizona.

Sponsor
Bristol-Myers Squibb
Study ID
NCT02935634
Phase
PHASE2
Status
Completed

Conditions

  • Advanced Gastric Cancer

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Nivolumab — BIOLOGICAL
    Specified dose on specified days
  • Ipilimumab — BIOLOGICAL
    Specified dose on specified days
  • Relatlimab — BIOLOGICAL
    Specified dose on specified days
  • BMS-986205 — BIOLOGICAL
    Specified dose on specified days
  • Rucaparib — DRUG
    Specified dose on specified days

Study Details

The purpose of this study is to evaluate the preliminary efficacy, safety, and tolerability of Nivolumab in combination with Ipilimumab or other treatment therapies in participants with advanced gastric cancer.

Key Dates

Start date
Nov 29, 2016
Status verified
May 2023
Primary completion
May 11, 2022
Completion
May 11, 2022

Study Design

Enrollment
190 participants (actual)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Active Comparator: Nivolumab + Ipilimumab
  • Experimental: Nivolumab + Relatlimab
  • Experimental: Nivolumab + BMS-986205
  • Experimental: Nivolumab + Rucaparib
  • Experimental: Ipilimumab + Rucaparib
  • Experimental: Nivolumab + Ipilimumab + Rucaparib

Primary Outcome Measure

Objective Response Rate (ORR) by Investigator [ Time Frame: From first dose of study treatment until progression or subsequent anticancer therapy, whichever occurs first (up to approximately 65 months) ]

Locations (16)

FacilityCityStateZIPSite coordinators
Mayo Clinic ArizonaPhoenixArizona85054-
Local Institution - 0020DuarteCalifornia91010-3000-
University Of ColoradoAuroraColorado80045-
Local Institution - 0032New HavenConnecticut06520-
Local Institution - 0036Washington D.C.District of Columbia20007-
UF Health Medical Oncology - Davis Cancer PavilionGainesvilleFlorida32610-
Local Institution - 0038JacksonvilleFlorida32224-
Local Institution - 0006BaltimoreMaryland21224-
Local Institution - 0017RochesterMinnesota55905-
Local Institution - 0003St LouisMissouri63110-
Local Institution - 0001HackensackNew Jersey07601-
Local Institution - 0007New YorkNew York10065-
Local Institution - 0002PortlandOregon97225-
Local Institution - 0005PhiladelphiaPennsylvania19111-
UPMCPittsburghPennsylvania15232-
Local Institution - 0004SeattleWashington98109-

Find similar trials in Phoenix, AZ

By research site
Mayo Clinic Arizona· Phoenix, AZLocal Institution - 0020· Duarte, CAUniversity Of Colorado· Aurora, COLocal Institution - 0032· New Haven, CTLocal Institution - 0036· Washington D.C., DCUF Health Medical Oncology - Davis Cancer Pavilion· Gainesville, FL

Related Studies